snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response

Abstract Neurofibromatosis Type 1 (NF1) is caused by loss of function variants in the NF1 gene. Most patients with NF1 develop skin lesions called cutaneous neurofibromas (cNFs). Currently the only approved therapeutic for NF1 is selumetinib, a mitogen -activated protein kinase (MEK) inhibitor. The...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Cameron Church, Christian X. Fay, Emil Kriukov, Hui Liu, Ashley Cannon, Lauren Ashley Baldwin, David K. Crossman, Bruce Korf, Margaret R. Wallace, Andrea M. Gross, Brigitte C. Widemann, Robert A. Kesterson, Petr Baranov, Deeann Wallis
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2024-06-01
سلاسل:	Acta Neuropathologica Communications
الموضوعات:	Neurofibromatosis Cutaneous neurofibroma Selumetinib Single nuclei sequencing Differential gene expression Ingenuity pathway analysis
الوصول للمادة أونلاين:	https://doi.org/10.1186/s40478-024-01821-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!